Clinical trials: HIV Infected Individuals
HIV Infections
Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals
Phase 4 study to evaluate the immunogenicity and Safety of the 17DD Yellow Fever vaccine in HIV infected individuals, compared to non-HIV-infected individuals.
- Trial name
- YF-HIV (NCT03132311)
- Testing
- Yellow Fever vaccination (17 DD Biomanguinhos)
- Where
- Brazil
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
HIV Infections
Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners
This study comprises two trials to evaluate the feasibility and cost-effectiveness of HIV self-testing strategies compared to standard of care among clients in outpatient departments (OPD; Aim 1) and the sexual partners of…
- Trial name
- NCT03271307
- Testing
- Optimized PITC, Facility HIVST, Index HIVST
- Where
- Malawi
- Volunteers
- 6,369 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Infections
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
To determine if treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of AIDS or ARC.
- Trial name
- NCT00000736
- Testing
- Zidovudine
- Where
- 43 sites in United States
- Volunteers
- 3,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Seropositivity
Lovastatin: Immunomodulatory Value Evaluation
The purpose of this study is to determine whether the long-term administration of statins may benefit the clinical and immunological evolution in HIV-1-infected individuals before the use of antiretroviral therapy is required.
- Trial name
- LIVE (NCT00721305)
- Testing
- Lovastatin
- Where
- Colombia
- Volunteers
- 112 people
- Sponsor
- Universidad de Antioquia
HIV
NNRTI/PI Toxicity Switch to Darunavir Study
The purpose of the study is to examine the effects of switching from antiretroviral combinations that includes efavirenz (Sustiva®), lopinavir/ritonavir (Kaletra®) or atazanavir/ritonavir (Reyataz®/Norvir®) in individuals…
- Trial name
- NCT00765154
- Testing
- darunavir, ritonavir
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- St Stephens Aids Trust
Leukemia, Lymphoma
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection.
- Conditions
- Leukemia, Lymphoma, HIV
- Trial name
- NCT01410344
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
HIV Infections
Gut Microbiota Changes of HIV Patients Before and After One Year of ART
HIV infection leads to destruction of CD4+T cells in the gut-associated lymphoid tissue (GALT) and promotes a decline in mechanical barrier functions of the gut mucosa, and the subsequent translocation of microbial products from…
- Trial name
- NCT04297501
- Testing
- Antiretroviral Therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
HIV
Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings
The purpose of this study is to conduct preparatory research needed to design a behavioral intervention to decrease sexual transmission risk behaviors in HIV-infected individuals in care and to determine whether a similar…
- Trial name
- HPTN063 (NCT01264185)
- Where
- 3 sites in Brazil, Thailand and 1 more
- Volunteers
- 751 people
- Sponsor
- HIV Prevention Trials Network
HIV Infections
A Long-term Follow-up of the HIV-NAT Cohort
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient.
- Trial name
- NCT00411983
- Where
- Thailand
- Volunteers
- 10,000 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH…
- Trial name
- NCT00000822
- Testing
- Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Immune Suppression
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).
People living with HIV could have different susceptibility and outcome to the SARS CoV-2 infection. The risk of SARS CoV-2 infection in this population could be no related to HIV infection, immunodepression or antiretroviral…
- Conditions
- Covid19, Immune Suppression, HIV-1-infection
- Trial name
- CoVIHDis (NCT04526977)
- Testing
- Immune response study
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
HIV Antiretroviral Therapy (ART) Adherence, Health Behavior
Improving Treatment Adherence in HIV-Infected Individuals
This study will develop and evaluate the efficacy of an individualized, interactive, computer software program delivered in conjunction with clinical care in increasing and supporting antiretroviral therapy adherence in…
- Trial name
- NCT00247611
- Testing
- LifeWindows Intervention Sessions, Control
- Where
- 5 sites in United States
- Volunteers
- 594 people
- Sponsor
- University of Connecticut
HIV Infections, Hepatitis C
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than interferon-alfa-2a (IFN) plus ribavirin for patients infected…
- Trial name
- NCT00008463
- Testing
- Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
- Where
- 24 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Proteinuria
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
The study is designed to evaluate the proportion of patients with tenofovir induced proteinuria that will resolve their proteinuria when the tenofovir containing nucleoside/nucleotide backbone is switched to a raltegravir…
- Trial name
- RALPIR (NCT01044771)
- Testing
- change from tenofovir to raltegravir
- Volunteers
- 20 people
- Sponsor
- Metropolis Medical
HIV-1 Infection
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
The objective is to obtain plasma samples from Human Immunodeficiency Virus Type 1 (HIV-1) infected individuals that have viral loads across the dynamic range of the Aptima HIV-1 assay.
- Trial name
- NCT02026752
- Where
- 9 sites in United States
- Volunteers
- 468 people
- Sponsor
- Gen-Probe, Incorporated
HIV Infection
PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection
A phase Ib partially blinded pilot study to evaluate the safety and immunological effects of PENNVAX-B with or without co-administration of constructs containing DNA encoding for the expression of either IL-12 or IL-15.
- Trial name
- NCT00775424
- Testing
- PENNVAX-B, GENEVAX IL-12-4532, IL-15 adjuvant
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pennsylvania
HIV Infections
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
Antiretroviral therapy (ART) dramatically reduces Human Immunodeficiency Virus (HIV) replication leading to restoration of immune function and a near normal life expectancy, but treatment is lifelong and there is no cure.
- Trial name
- NCT03198559
- Testing
- Disulfiram, (National Drug Code) NDC 0378-4141-01, Vorinostat, NDC 00006-0568-40
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- University of Melbourne
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
HIV-1-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses to HIV. The DNA-based vaccine in this study is designed to boost the immune system's responses against many…
- Trial name
- NCT00052182
- Testing
- EP HIV-1090
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)